Nectar Lifesciences Ltd Stock Price Today (NSE: NECLIFE)
Fundamental Score
Nectar Lifesciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Nectar Lifesciences Ltd share price today is ₹12.01, down 0.66% on NSE/BSE as of 18 June 2026. Nectar Lifesciences Ltd (NECLIFE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹390.66 (Cr). The 52-week high for NECLIFE share price is ₹23.87 and the 52-week low is ₹9.30. The company has a Return on Equity (ROE) of -11.23% and a debt-to-equity ratio of 0.64.
Nectar Lifesciences Ltd Share Price Chart — NSE/BSE Historical Performance
Nectar Lifesciences Ltd share price chart: -0.56% return over the past month. 52-week high ₹23.87, 52-week low ₹9.30.
Nectar Lifesciences Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹12.02 | ₹12.10 | ₹11.90 | ₹12.01 | 2.74L (Cr) | |
| ₹12.48 | ₹12.49 | ₹12.01 | ₹12.09 | 1.79L (Cr) | |
| ₹12.49 | ₹12.70 | ₹12.25 | ₹12.45 | 1.30L (Cr) | |
| ₹12.49 | ₹12.49 | ₹12.49 | ₹12.49 | 0.00 (Cr) | |
| ₹12.21 | ₹12.75 | ₹12.07 | ₹12.49 | 4.60L (Cr) | |
| ₹12.20 | ₹12.58 | ₹12.20 | ₹12.27 | 1.37L (Cr) | |
| ₹12.06 | ₹12.61 | ₹12.03 | ₹12.15 | 2.41L (Cr) | |
| ₹12.21 | ₹12.36 | ₹12.00 | ₹12.06 | 1.44L (Cr) | |
| ₹12.40 | ₹12.55 | ₹12.10 | ₹12.21 | 90.59K (Cr) | |
| ₹12.47 | ₹12.47 | ₹12.00 | ₹12.27 | 1.24L (Cr) |
Nectar Lifesciences Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹12.48 | ₹12.49 | ₹11.90 | ₹12.01 | -3.77% | |
| ₹12.41 | ₹14.91 | ₹11.77 | ₹12.45 | +0.32% | |
| ₹9.48 | ₹13.03 | ₹9.48 | ₹12.41 | +30.91% | |
| ₹12.00 | ₹12.15 | ₹9.30 | ₹9.30 | -22.50% | |
| ₹13.14 | ₹14.34 | ₹12.00 | ₹12.20 | -7.15% | |
| ₹19.62 | ₹20.90 | ₹13.26 | ₹13.52 | -31.09% | |
| ₹18.00 | ₹22.40 | ₹16.11 | ₹19.41 | +7.83% | |
| ₹15.30 | ₹16.99 | ₹13.51 | ₹16.99 | +11.05% | |
| ₹14.11 | ₹16.54 | ₹13.10 | ₹15.51 | +9.92% | |
| ₹14.30 | ₹17.38 | ₹13.90 | ₹14.40 | +0.70% | |
| ₹16.41 | ₹16.90 | ₹13.05 | ₹14.27 | -13.04% | |
| ₹22.22 | ₹23.87 | ₹15.51 | ₹16.41 | -26.15% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Nectar Lifesciences Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Nectar Lifesciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NECLIFE across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Strong Cash Generation (₹604.40 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
8 factors identified
Below-Average Return on Equity (-11.23%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-5.36%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-43.48%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-6.77% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-4.08x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.70%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (98.77%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Nectar Lifesciences Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Nectar Lifesciences Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Nectar Lifesciences LtdNectar Lifescie...Selected✓ NECLIFE • 532649 | 0/100 | ₹12.01₹12 | ₹390.66₹390.66 | — — | -11.23%Poor -11.23% Poor | -5.36%Poor -5.36% Poor | 0.64Good 0.6 Good | — — | -6.77%Poor -6.77% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Nectar Lifesciences Ltd PE Ratio History
Historical price-to-earnings ratio for NECLIFE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.22 | ₹38.98 | 177.2x |
| FY 2022 | ₹1.12 | ₹24.55 | 21.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Nectar Lifesciences Ltd Dividend History
Annual cash dividends paid by NECLIFE — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2021 | ₹1.12 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Nectar Lifesciences Ltd Quarterly Performance
Latest quarterly metrics for NECLIFE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-0.52%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-43.48%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-6.77%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Nectar Lifesciences Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NECLIFE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Nectar Lifesciences Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Nectar Lifesciences Ltd (NECLIFE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Nectar Lifesciences Ltd
About NECLIFE (Nectar Lifesciences Ltd)
Nectar Lifesciences Ltd is a dynamic pharmaceutical entity, dedicated to the discovery, development, and commercialization of innovative healthcare solutions. Rooted in a strong fo...undation of scientific expertise and manufacturing excellence, NECLIFE operates as a global player, actively contributing to the advancement of medical treatments. The company's commitment extends beyond mere production, encompassing a comprehensive approach that includes research and development, rigorous quality control, and a proactive pursuit of therapeutic advancements. NECLIFE strives to address unmet medical needs, focusing on enhancing patient outcomes through the delivery of safe, effective, and accessible pharmaceutical products. At the heart of NECLIFE's operations lies a sophisticated portfolio of pharmaceutical offerings, including active pharmaceutical ingredients (APIs) and advanced intermediates. These products serve as crucial building blocks in the creation of numerous life-saving medications. NECLIFE specializes in the production of cephalosporins, a critical class of antibiotics widely used in combating bacterial infections. Through continuous innovation and a dedication to process optimization, the company manufactures a broad spectrum of cephalosporin-based products, serving diverse therapeutic needs across the globe. NECLIFE's focus on quality and consistency ensures that its ingredients meet the highest international standards. NECLIFE's strategic vision encompasses a strong global presence, actively engaging in the distribution, marketing, and sales of its pharmaceutical products in India and across international markets. With a commitment to ethical business practices and a customer-centric approach, NECLIFE has established a reliable supply chain and a trusted network of partners. The company's unwavering dedication to scientific advancement and its ability to adapt to evolving healthcare demands positions it as a key player in the pharmaceutical industry, ready to tackle the challenges of tomorrow and improve global health.
Company Details
Key Leadership
Corporate Events
NECLIFE Share Price: Frequently Asked Questions
What is the current share price of Nectar Lifesciences Ltd?
Nectar Lifesciences Ltd (NECLIFE) trades at ₹12.01 on NSE and BSE. Market cap ₹390.66 (Cr). Educational data only.
What is the P/E ratio of Nectar Lifesciences Ltd?
Nectar Lifesciences Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Nectar Lifesciences Ltd?
Nectar Lifesciences Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Nectar Lifesciences Ltd pay dividends?
Nectar Lifesciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Nectar Lifesciences Ltd?
Nectar Lifesciences Ltd has ROE of -11.23%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Nectar Lifesciences Ltd?
Nectar Lifesciences Ltd has debt-to-equity of 0.64.
Is Nectar Lifesciences Ltd a good investment?
Bull Run gives Nectar Lifesciences Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.